Immune checkpoint inhibitors in cancer treatment
The advent and validation of immune checkpoint inhibitors targeting the T cell receptors PD1 and CTLA have been 'game changers' in clinical cancer therapy. Initially approved for melanoma, lung cancer, and kidney cancer these therapies have now gained substantial inroads in a diversity of tumor types as first or second-line therapy and promise to extend the lives of millions of more cancer patients. However, there is critical ongoing research attempting to optimize the therapeutic utility of these agents. Current investigations include analysis of tumor molecular profiles most apt to respond to specific checkpoint immunotherapy regimens, optimal timing of treatment and combination with chemotherapy, radiation, and molecularly targeted anti-cancer agents, and the potential to enhance responsiveness of checkpoint inhibition with concurrent use of novel therapies targeting innate or adaptive immunity. Research in all these areas has exploded at both the clinical and experimental levels. As such, these burgeoning reports comprise a valued addition and are a new cornerstone in Springer Nature's topical online collections in cancer research.
The editors of the journals Oncogene, Blood Cancer Journal, Leukemia and Cancer Gene Therapy welcome future submissions to expand this collection further.
